Tempus AI Class Action Lawsuit: Lead Plaintiff Deadline August 12, 2025
PorAinvest
lunes, 11 de agosto de 2025, 4:19 am ET1 min de lectura
AZN--
Key Allegations
The lawsuit alleges that Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins, and were self-funded. Additionally, the credibility of Tempus AI's joint venture with SoftBank Group Corporation was at risk due to the appearance of "round-tripping" capital to create revenue. The company's acquisition of Ambry Genetics Corporation was also criticized for its aggressive and potentially unethical billing practices. Furthermore, AstraZeneca PLC reduced its financial commitments to Tempus AI through a questionable "pass-through payment" via a joint agreement between Tempus AI, AstraZeneca, and Pathos AI, Inc. These issues revealed weaknesses in core operations and revenue prospects.
Lead Plaintiff Process
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the lawsuit. The lead plaintiff can select a law firm of its choice to litigate the case. Investors' ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Contact Information
Interested parties can provide their information or contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller Rudman & Dowd LLP by calling 800/449-4900 or via email at [email protected]. More details can be found on the law firm's website [1].
References
[1] https://www.rgrdlaw.com/cases-tempus-ai-inc-class-action-lawsuit-tem.html
[2] https://www.prnewswire.com/news-releases/tem-investors-have-opportunity-to-lead-tempus-ai-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302526160.html
[3] https://www.globenewswire.com/news-release/2025/08/07/3128861/35454/en/TEMPUS-AI-SHAREHOLDER-ALERT-CLAIMSFILER-REMINDS-INVESTORS-WITH-LOSSES-IN-EXCESS-OF-100-000-of-Lead-Plaintiff-Deadline-in-Class-Action-Lawsuit-Against-Tempus-AI-Inc-TEM.html
TEM--
Purchasers of Tempus AI common stock between August 6, 2024 and May 27, 2025 are eligible to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges violations of the Securities Exchange Act of 1934 against Tempus AI and certain executives. The deadline to seek appointment is August 12, 2025. Interested parties can provide information or contact attorneys J.C. Sanchez or Jennifer N. Caringal at 800/449-4900 or [email protected].
San Diego, Aug. 11, 2025 — Purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025 have until August 12, 2025 to seek appointment as lead plaintiff in a class action lawsuit alleging violations of the Securities Exchange Act of 1934. The lawsuit, captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), charges Tempus AI and certain executives with making false and/or misleading statements and/or failing to disclose significant issues related to the company's operations and financial reporting.Key Allegations
The lawsuit alleges that Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins, and were self-funded. Additionally, the credibility of Tempus AI's joint venture with SoftBank Group Corporation was at risk due to the appearance of "round-tripping" capital to create revenue. The company's acquisition of Ambry Genetics Corporation was also criticized for its aggressive and potentially unethical billing practices. Furthermore, AstraZeneca PLC reduced its financial commitments to Tempus AI through a questionable "pass-through payment" via a joint agreement between Tempus AI, AstraZeneca, and Pathos AI, Inc. These issues revealed weaknesses in core operations and revenue prospects.
Lead Plaintiff Process
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the lawsuit. The lead plaintiff can select a law firm of its choice to litigate the case. Investors' ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Contact Information
Interested parties can provide their information or contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller Rudman & Dowd LLP by calling 800/449-4900 or via email at [email protected]. More details can be found on the law firm's website [1].
References
[1] https://www.rgrdlaw.com/cases-tempus-ai-inc-class-action-lawsuit-tem.html
[2] https://www.prnewswire.com/news-releases/tem-investors-have-opportunity-to-lead-tempus-ai-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302526160.html
[3] https://www.globenewswire.com/news-release/2025/08/07/3128861/35454/en/TEMPUS-AI-SHAREHOLDER-ALERT-CLAIMSFILER-REMINDS-INVESTORS-WITH-LOSSES-IN-EXCESS-OF-100-000-of-Lead-Plaintiff-Deadline-in-Class-Action-Lawsuit-Against-Tempus-AI-Inc-TEM.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios